CYP19A1 and cancer: All patients except five who were lost to follow-up (n = 4) or had ER-negative cancer after surgery (n = 1) received adjuvant tamoxifen (n = 366, 78.5%) or aromatase inhibitor therapy (n = 95, 20.4%).